{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:56:15Z","timestamp":1789062975619,"version":"build-2803163510"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1129600"],"award-info":[{"award-number":["OPP1129600"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>A population pharmacokinetic (PopPK) model for pretomanid was developed using data from 14 studies in the pretomanid development program: six phase 1 studies, six phase 2 studies, and two phase 3 studies. The final analysis data set contained 17,725 observations from 1,054 subjects, including healthy subjects and subjects with drug-sensitive, multidrug-resistant, or extensively drug-resistant pulmonary tuberculosis dosed pretomanid in monotherapy or combination therapy for up to 6 months.<\/jats:p>","DOI":"10.1128\/aac.00907-19","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T09:32:41Z","timestamp":1565256761000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":32,"title":["Population Pharmacokinetics of the Antituberculosis Agent Pretomanid"],"prefix":"10.1128","volume":"63","author":[{"given":"David H.","family":"Salinger","sequence":"first","affiliation":[{"name":"Certara, Inc., Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishak","family":"Subramoney","sequence":"additional","affiliation":[{"name":"Certara, Inc., Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Everitt","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Nedelman","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global tuberculosis report\u20142018","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Global tuberculosis report\u20142018. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"e_1_3_3_3_2","volume-title":"49th Abstracts of the World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, abstr OA03-213-215","author":"Conradie F","year":"2018","unstructured":"Conradie F, Diacon A, Everitt D, Mendel C, Crook A, Howell P, Comins K, Spigelman M. 2018. Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid. 49th Abstracts of the World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, abstr OA03-213-215. https:\/\/www.abstractserver.com\/TheUnion2018\/TheUnion2018_Abstracts_Web.pdf."},{"key":"e_1_3_3_4_2","volume-title":"Abstracts of the Conference on Rotoviruses and Opportunistic Infections, abstr 724-LB","author":"Dawson R","year":"2017","unstructured":"Dawson R, Harris K, Conradie A, Burger D, Murray S, Mendel C, Spigelman M. 2017. Efficacy of bedaquiline, pretomanid, moxifloxacin, and PZA (BPaMZ) against DS- and MDR-TB. Abstracts of the Conference on Rotoviruses and Opportunistic Infections, abstr 724-LB. http:\/\/www.croiconference.org\/sessions\/efficacy-bedaquiline-pretomanid-moxifloxacin-pza-bpamz-against-ds-mdr-tb."},{"key":"e_1_3_3_5_2","unstructured":"International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. 2019. ICH Geneva Switzerland. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E4\/Step4\/E4_Guideline.pdf. Accessed 12 July 2019."},{"key":"e_1_3_3_6_2","volume-title":"Guidance for industry: population pharmacokinetics","author":"FDA","year":"2019","unstructured":"FDA. 2019. Guidance for industry: population pharmacokinetics. U.S. Department of Health and Human Services\/Food and Drug Administration\/Center for Drug Evaluation and Research, Bethesda, MD."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00798-13"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00106-09"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03332-14"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02359-17"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9066-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-9931-1"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-015-9460-y"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12161"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/009286159803200310"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00112-09"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01354-09"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06125-11"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61080-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62002-X"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1801OC"},{"key":"e_1_3_3_25_2","volume-title":"Guidance for industry: pharmacokinetics in patients with impaired renal function \u2013 study design, data analysis, and impact on dosing and labeling","author":"FDA","year":"2010","unstructured":"FDA. 2010. Guidance for industry: pharmacokinetics in patients with impaired renal function \u2013 study design, data analysis, and impact on dosing and labeling. U.S. Department of Health and Human Services\/Food and Drug Administration\/Center for Drug Evaluation and Research, Bethesda, MD."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00907-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00907-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:38:54Z","timestamp":1645479534000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00907-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1128\/AAC.00907-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00907-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"2019-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00907-19"}}